반응식
[CH3:1][C:2]1[N:3]=[CH:4][C:5]([NH:8][C:9]2[C:18]3[C:13](=[CH:14][CH:15]=[C:16]([OH:19])[CH:17]=3)[N:12]=[CH:11][N:10]=2)=[N:6][CH:7]=1.C(O[CH:23](OCC)[CH2:24][O:25][C:26]1[CH:27]=[CH:28][C:29](F)=[N:30][CH:31]=1)C.C[NH2:37].O1[CH2:42][CH2:41]CC1>>[CH2:41]([NH:37][CH2:23][CH2:24][O:25][C:26]1[CH:27]=[CH:28][C:29]([O:19][C:16]2[CH:17]=[C:18]3[C:13](=[CH:14][CH:15]=2)[N:12]=[CH:11][N:10]=[C:9]3[NH:8][C:5]2[CH:4]=[N:3][C:2]([CH3:1])=[CH:7][N:6]=2)=[N:30][CH:31]=1)[CH3:42]참가 물질
4
실험 절차
Using 4-[(5-methylpyrazin-2-yl)amino]quinazolin-6-ol, 5-(2,2-diethoxyethoxy)-2-fluoropyridine and 2 Methylamine/tetrahydrofuran solution, and in the same manner as in Example 31 or according to a method similar to it or according to a combination thereof with an ordinary method, the entitled compound (52 mg) was obtained as a pale yellow amorphous solid.
출처 및 근거
- ORD 기록
- ord-2023a86ea0534b57a7e4088f55c86661
- 출처 데이터셋
- uspto-grants-2014_09
- 특허 번호
- US08846700B2
연결된 노트
불러오는 중…